Ernst & Young Bullish On Medtech's Fusion With Innovation
The medtech industry grew by 5% last year, with revenues from US- and Europe-based medtechs reaching $364.4bn in 2016. Meanwhile, net income rose by 17% to reach $16bn in 2016, according to Ernst & Young's annual medtech "Pulse of the industry" report, released today to coincide with The MedTech Conference in San Jose. With global funding expanding, in particular in Asia, medtechs are well positioned for growth, but only those willing to embrace the digital revolution are poised to win.
You may also be interested in...
More than 75% of Fortune 500 life-science companies may fall out of that ranking by 2023 amid rising competition from tech giants like Apple, Microsoft and Alphabet, as well as smaller tech players that offer data-driven health services and products that meet the needs of a changing value-based and consumer-driven health-care environment, according to a new Ernst & Young report.
While August may have broken the short summer bull run, last month's batch of venture fundraisings did have one redeeming feature – it recorded the biggest Series A round this year to date, a $50m deal by liquid biopsy company Karius.
3D printing has been hailed as a potentially game-changing technology for different industries. Biomedical applications, in particular, have garnered much attention when patients were able to receive 3D-printed, customized, lifesaving medical interventions. But aside from these niche markets for personalized medical devices, can 3D printing ever become mainstream in health care? This article, a guest column from leaders at the Boston Consulting Group, explores what the benefits of 3D-printed devices are and how they are driving the uptake of this technology. It also assesses how fast this adoption is happening and evaluates how – and in which biomedical applications and device markets – 3D printing could best enhance products and allow medtech manufacturers to grow their business.